Código QR

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer

Abstract Background Trastuzumab-induced cardiotoxicity (TIC) can lead to early discontinuation of adjuvant therapy, however there is limited evidence on long-term survival outcomes in patients with operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) experiencing trea...

Descrición completa

Gardado en:
Principais autores: Sagar Sardesai, Jasmine Sukumar, Mahmoud Kassem, Marilly Palettas, Julie Stephens, Evan Morgan, Daniel Addison, Ragavendra Baliga, Daniel G. Stover, Jeffrey VanDeusen, Nicole Williams, Mathew Cherian, Maryam Lustberg, Robert Wesolowski, Bhuvaneswari Ramaswamy
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2020-11-01
Series:Cardio-Oncology
Assuntos:
HER2
Breast cancer
Trastuzumab
Cardio-oncology
Chemotherapy
Acceso en liña:http://link.springer.com/article/10.1186/s40959-020-00081-9
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares